DuPont de Nemours, Inc.

NOTE 7 -SUPPLEMENTARY INFORMATION

1. The three and nine months ended September 30, 2025 and 2024 include interest on cash. Fluctuations in interest income are due to changes in cash balances and/or changes in interest rates. Includes interest income earned on cash received and held in escrow associated with the Qnity Notes of $9 million. Refer to Note 21 for further details.

2. The nine months ended September 30, 2024 reflects the loss on the partial redemption of an aggregate principal amount of the 2038 Notes.

3. The three months ended September 30, 2025 includes the non-cash mark-to-market net gain related to the 2022 Swaps and 2024 Swaps offset by the cash settlement loss on the 2024 Swaps and the interest settlement loss on the 2022 Swaps. The nine months ended September 30, 2025 includes the non-cash mark-to-market net gain related to the 2022 Swaps and 2024 Swaps offset by the cash settlement loss on the 2024 swaps and the interest settlement loss on the 2022 Swaps. The three and nine months ended September 30, 2024 includes non-cash mark-to-market gain related to the 2022 Swaps and 2024 Swaps offset by the interest settlement loss on the 2022 Swaps. Refer to Note 19 for further details.

4. The three and nine months ended September 30, 2025, includes a benefit related to adjustments of the Donatelle contingent earn-out liability. Refer to Note 3 for further details.

Cash, Cash Equivalents and Restricted Cash

"Cash, cash equivalents and restricted cash at end of period" in the interim Consolidated Statements of Cash Flows includes the following:

At September 30, 2025 and December 31, 2024, the Company had "Cash and cash equivalents" in the interim Condensed Consolidated Balance Sheets $1,955 million and $1,843 million, respectively.

At September 30, 2025 and December 31, 2024, the Company had $1,830 million and $6 million, respectively, within “Restricted cash and cash equivalents” in the Consolidated Balance Sheets. In August 2025, Qnity, a wholly-owned subsidiary of DuPont, issued senior secured notes and senior unsecured notes. The gross proceeds were deposited into an escrow account. At September 30, 2025, the Company had approximately $1,825 million recorded within “Restricted cash and cash equivalents" related to Qnity Notes. See Note 13 for further discussion of the Qnity Notes.

At September 30, 2025 and December 31, 2024, the Company also had $37 million and $36 million, respectively, within "Restricted cash and cash equivalents - noncurrent" in the interim Consolidated Balance Sheets. The majority of the balance during both periods is attributable to the MOU cost sharing arrangement. Additional information can be found in Note 14.

Within discontinued operations related to the Aramids Divestiture the Company had $4 million and $7 million within "Cash and cash equivalents" at September 30, 2025 and December 31, 2024, respectively. Additional information can be found in Note 4.

Accrued and Other Current Liabilities

"Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets were $1,103 million at September 30, 2025 and $988 million at December 31, 2024. Accrued payroll, which is a component of "Accrued and other current liabilities," was $346 million at September 30, 2025 and $365 million at December 31, 2024. No other component of "Accrued and other current liabilities" was more than 5 percent of total current liabilities at September 30, 2025 and at December 31, 2024.